Search Results - "Goldberg, S.B."

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer by Hastings, K., Yu, H.A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C.A., Liu, Z., Henick, B.S., Wurtz, A., Cai, G., Plodkowski, A.J., Long, N.M., Halpenny, D.F., Killam, J., Oliva, I., Schultz, N., Riely, G.J., Arcila, M.E., Ladanyi, M., Zelterman, D., Herbst, R.S., Goldberg, S.B., Awad, M.M., Garon, E.B., Gettinger, S., Hellmann, M.D., Politi, K.

“…Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however,…”
Get full text

Cost Effectiveness Analysis of Stereotactic Body Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer by Lester-Coll, N.H, Goldberg, S.B, Yu, J.B, Decker, R.H

Get full text

3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC by Goldberg, S.B, Balmanoukian, A, Chaft, J, Rizvi, N, Sanborn, R.E, Rebelatto, M.C, Narwal, R, Robbins, P.B, Gu, Y, Karakunnel, J.J, Antonia, S

Get full text

Real-World Practice Patterns of Immunotherapy, Chemotherapy, and Targeted Therapy with Radiation Therapy in Early-Stage Node-Negative Non-Small Cell Lung Cancer by Oh, P., Sasse, A., Wells, N., Kim, S.Y., Goldberg, S.B., Park, H.S.M.

“…Large prospective studies have demonstrated the clinical benefit of chemotherapy and immunotherapy with radiotherapy (RT) in unresectable locally advanced…”
Get full text

Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Early-Stage Non-Small Cell Lung Cancer (NSCLC) by Liu, G., Zhang, J., Wang, Y., Burgener, J., Hall, O., Shen, S.Y., Pienkowski, M., Huang, S.H., Sosa, E., Polio, A., Goldberg, S.B., Mazzone, P., Bratman, S., Licon, A., Brown, K., Allen, B., Hartman, A.R., De Carvalho, D.D., Park, B.

Get full text

162P Population pharmacokinetic modeling of tremelimumab in patients (pts) with advanced solid tumors by Even, C., Goldberg, S.B., Siu, L.L., Planchard, D., Hwang, M., Chen, C.C-K., He, J., Song, X., Zhou, D., Doake, R., Krug, L., Peters, S.

Get full text

329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib by Riess, J.W., De Langen, J.A., Piotrowska, Z., Goldberg, S.B., Goldman, J.W., Okamoto, I., Ponce Aix, S., Teraoka, S., Ambrose, H., Tang, K.H., Maidment, J., Merchan Ruiz, B., Hewson, N., Cosaert, J., Yu, H.A.

Get full text

1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib by De Langen, J., Cho, B.C., Piotrowska, Z., Le, X., Goldberg, S.B., Goldman, J.W., Okamoto, I., Hewson, N., Maidment, J., Tang, K.H., Veney, N., Cosaert, J., Lau, J., Dressman, M., Ambrose, H., Riess, J.W., Yu, H.A.

Get full text

Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) by Campbell, A.M., Cai, W.L., Burkhardt, D., Gettinger, S.N., Goldberg, S.B., Amodio, M., Kaech, S., Krishnaswamy, S., Decker, R.H.

Get full text

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice by Sequist, L.V., Heist, R.S., Shaw, A.T., Fidias, P., Rosovsky, R., Temel, J.S., Lennes, I.T., Digumarthy, S., Waltman, B.A., Bast, E., Tammireddy, S., Morrissey, L., Muzikansky, A., Goldberg, S.B., Gainor, J., Channick, C.L., Wain, J.C., Gaissert, H., Donahue, D.M., Muniappan, A., Wright, C., Willers, H., Mathisen, D.J., Choi, N.C., Baselga, J., Lynch, T.J., Ellisen, L.W., Mino-Kenudson, M., Lanuti, M., Borger, D.R., Iafrate, A.J., Engelman, J.A., Dias-Santagata, D.

“…Personalizing non-small-cell lung cancer (NSCLC) therapy toward oncogene addicted pathway inhibition is effective. Hence, the ability to determine a more…”
Get full text

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib by Yu, H.A., Ambrose, H., Baik, C., Cho, B.C., Cocco, E., Goldberg, S.B., Goldman, J.W., Kraljevic, S., de Langen, A.J., Okamoto, I., Piotrowska, Z., Pluta, M., Powar, S., Aransay, N. Reguart, Riess, J.W., Le, X.

Get full text

Cost Effectiveness Analysis of Stereotactic Body Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Outcomes/Health Services Research by Lester-Coll, N.H., Goldberg, S.B., Yu, J.B., Decker, R.H.

Get full text

Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma by Campbell, A.M., Herbst, R.S., Gettinger, S.N., Goldberg, S.B., Kluger, H.M., Chiang, A.C., Lilenbaum, R.C., Schalper, K.A., Sowell, R., Kaech, S., Decker, R.H.

Get full text

First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI by Husain, H., Martins, R.G., Goldberg, S.B., Senico, P., Ma, W., Masters, J., Pathan, N., Kim, D-W., Socinski, M.A., Goldberg, Z., Cho, B.C.

Get full text

Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA by Goldberg, S.B., Narayan, A., Kole, A.J., Decker, R.H., Teysir, J., Carriero, N.J., Lee, A., Nemati, R., Nath, S.K., Mane, S.M., Deng, Y., Sukumar, N., Zelterman, D., Boffa, D.J., Politi, K., Gettinger, S.N., Wilson, L.D., Herbst, R.S., Patel, A.A.

Get full text

Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study by Ahn, M.-J., Chiu, C.-H., Cheng, Y., Han, J.-Y., Goldberg, S.B., Greystoke, A., Crawford, J., Zhao, Y., Huang, X., Johnson, M., Vishwanathan, K., Mendoza-Naranjo, A., Mok, T.S.K.

Get full text

Synbiotics-supplemented amino acid-based formula supports adequate growth in cow's milk allergic infants by Burks, A. Wesley, Harthoorn, Lucien F., Van Ampting, Marleen T. J., Oude Nijhuis, Manon M., Langford, Jane E., Wopereis, Harm, Goldberg, Steven B., Ong, Peck Y., Essink, Brandon J., Scott, Robert B., Harvey, Bryan M.

“…Background Children with cow's milk allergy (CMA) are at risk for inadequate nutritional intake and growth. Dietary management of CMA, therefore, requires…”
Get full text

Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC by Ahn, M.-J., Chiu, C.-H., Cheng, Y., Han, J.-Y., Goldberg, S.B., Greystoke, A., Crawford, J., Zhao, Y., Huang, X., Johnson, M., Vishwanathan, K., Mendoza-Naranjo, A., Mok, T.

Get full text

418O Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC by Rizvi, N., Balmanoukian, A., Goldberg, S.B., Chaft, J., Sanborn, R.E., Rebelatto, M.C., Narwal, R., Robbins, P.B., Gu, Y., Karakunnel, J.J., Antonia, S.

Get full text

Stereo vision and rover navigation software for planetary exploration by Goldberg, S.B., Maimone, M.W., Matthies, L.

“…NASA's Mars Exploration Rover (MER) missions will land twin rovers on the surface of Mars in 2004. These rovers will have the ability to navigate safely…”
Get full text